Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering

Rhea-AI Summary

Advanced Biomed Inc. (NASDAQ: ADVB) has successfully completed its Initial Public Offering (IPO), raising $6.56 million in gross proceeds through the sale of 1,640,000 common stock shares at $4.00 per share. Trading began on the Nasdaq Capital Market on March 6, 2025, under ticker 'ADVB'.

The company has granted the underwriter a 45-day option to purchase up to 246,000 additional shares. The IPO proceeds will fund:

• IVD clinical research, chip design and development, facility upgrades, and market expansion
• Marketing and sales initiatives
• General working capital

Advanced Biomed, established in 2014, specializes in microfluidic technology for cancer detection and treatment, offering innovative devices including A+Pre, AC-1000, A+CellScan, and A+SCDrop, along with corresponding biochips and immunostaining kits.

Positive

• Successfully raised $6.56M through IPO
• Achieved Nasdaq Capital Market listing
• Diversified product portfolio in cancer detection
• Established presence since 2014 with proprietary technology
• Geographic expansion plans for North America and Europe

Negative

• Small IPO size may limit growth potential
• Potential dilution from 246,000 share over-allotment option
• Operating in highly competitive biotech sector
• Early-stage company with significant R&D expenses

Insights

Financial Analyst

Advanced Biomed's $6.56 million IPO represents a modest capital raise for a biotech company, particularly in the competitive cancer diagnostics space. At $4.00 per share, the offering price positioned slightly higher than the current $3.65 trading level, suggesting some initial market adjustment following the listing.

The company's microfluidic technology platform targeting cancer screening, diagnosis, and treatment presents diversified commercial potential across the oncology care continuum. Their product portfolio spanning early detection (A+Pre), circulating tumor cell enrichment (AC-1000), cell scanning (A+CellScan), and single-cell technologies (A+SCDrop) demonstrates a comprehensive approach to liquid biopsy.

The allocation of proceeds reveals strategic priorities: strengthening their diagnostic technology, expanding market reach, and building sales capabilities. However, the relatively small raise may limit the scope of these initiatives. With no revenue figures disclosed, investors should monitor cash burn rates against this capital infusion.

The firm commitment underwriting structure provided deal certainty but likely came with substantial fees, reducing net proceeds. While the overallotment option could potentially add another $984,000 if exercised within 45 days, this depends on market performance.

Being Taiwan-based with expansion plans for China, North America, and Europe signals global ambitions but also regulatory complexity across different markets. The company will need to navigate varying approval pathways for their diagnostic technologies, potentially requiring additional capital raises before achieving meaningful revenue.

Oncology Specialist

Advanced Biomed's technology platform addresses critical needs in cancer management through liquid biopsy approaches. Their focus on circulating tumor cells (CTCs) and tumor markers in blood samples represents a less invasive alternative to traditional tissue biopsies, potentially enabling earlier detection and more frequent monitoring.

The company's integrated product ecosystem is noteworthy - spanning from initial screening devices to specialized CTC enrichment and single-cell analysis technologies. This comprehensive approach could provide clinicians with a continuous diagnostic pipeline from early detection through treatment monitoring.

Their immunostaining kits (A+CTCE, A+CTCM, A+EMT, A+CM) using multiplexed fluorescent-labeled antibodies suggest capabilities for detailed molecular characterization of CTCs, potentially enabling more personalized treatment selection. The A+LCGuard product specifically targeting lung nodule characterization addresses an important clinical challenge in distinguishing benign from malignant pulmonary findings.

However, the press release lacks specific performance data on sensitivity, specificity, or clinical validation studies that would typically support adoption of diagnostic technologies. While microfluidic CTC platforms have demonstrated promise in research settings, clinical implementation faces challenges in standardization, reproducibility, and demonstrating improved patient outcomes.

The competitive landscape for liquid biopsy technologies is intensifying, with larger companies and numerous startups pursuing similar approaches. Advanced Biomed will need compelling clinical data and regulatory approvals to differentiate their offerings and gain market traction with the capital they've raised.

Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the closing of its initial public offering (the "Offering") of 1,640,000 shares of common stock (the “Shares”), at a public offering price of $4.00 per share for total gross proceeds of $6.56 million before deducting underwriting discounts and offering expenses. The Shares began trading on the Nasdaq Capital Market on March 6, 2025 under the ticker symbol “ADVB.”

The Offering was conducted on a firm commitment basis. In addition, the Company has granted the underwriter an option, exercisable within 45 days from the closing date of the Offering, to purchase up to an additional 246,000 shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotment, if any.

Proceeds from the Offering will be used for: (i) invitro diagnostics (IVD) clinical research, chip design and development, upgrade facilitates, and expansion to other markets; (ii) marketing and sales, and (iii) general working capital.

Craft Capital Management LLC acted as underwriter for the Offering (the “Underwriter”). VCL Law LLP acted as U.S. securities counsel to the Company, and Ortoli Rosenstadt LLP acted as U.S. securities counsel to the Underwriter.

The Offering was conducted pursuant to the Company’s registration statement on Form S-1 (File No. 333-272110), as amended, in connection with the Offering (the “Registration Statement”) previously filed with the Securities and Exchange Commission ("SEC") and subsequently declared effective by the SEC on February 11, 2025. The Offering was made only by means of a prospectus. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, copies of the prospectus relating to the Offering may be obtained from Craft Capital Management LLC by email at info@craftcm.com, by standard mail to 377 Oak St, Lower Concourse, Garden City, NY 11530, or by telephone at +1 (800) 550-8411.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration nor shall there be any offer, solicitation or sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Advanced Biomed Inc.

Since 2014, Advanced Biomed Inc. has been focusing on the integration of multiple interdisciplinary technologies and established its own microfluidic technology platform. The Company aims to provide rapid and affordable assay products and services to cancer patients. The Company has a range of innovative devices, including A+Pre, AC-1000, A+CellScan, and A+SCDrop, along with three corresponding biochips: A+Pre Chip, AC-1000 CTC Enrichment Chip, and A+CellScan Chip. The Company’s technologies and products can be used for early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers in blood samples, capture of single circulating tumor cells, and single-cell sorting and determination. Additionally, the Company has completed the research and development stage for four matching immunostaining kits, A+CTCE, A+CTCM, A+EMT, and A+CM, utilizing multiplexed staining with fluorescent-labeled antibodies to identify tumor cell types. The Company has also introduced A+LCGuard, a product designed for early screening of lung cancer to assist in the determination of benign and malignant pulmonary nodules. With the Company's primary operations, design, and development based in Taiwan, Advanced Biomed is expanding in China while preparing for the establishment of operation centers in North America and Europe.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may,” "will,” "intend," "should," "believe," "expect," "anticipate," "project," "estimate," “continue” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the Registration Statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Advanced Biomed Inc.

Mingze Yin
Email: yinmingze@advbiomedicine.com
Mobile: +852-95050429

FAQ

How much did Advanced Biomed (ADVB) raise in its IPO?

Advanced Biomed raised $6.56 million in gross proceeds through its IPO by selling 1,640,000 shares at $4.00 per share.

When did ADVB stock begin trading on Nasdaq?

ADVB stock began trading on the Nasdaq Capital Market on March 6, 2025.

What will Advanced Biomed use the IPO proceeds for?

The proceeds will fund IVD clinical research, chip development, facility upgrades, market expansion, marketing and sales initiatives, and general working capital.

What products does Advanced Biomed (ADVB) offer for cancer detection?

ADVB offers devices like A+Pre, AC-1000, A+CellScan, and A+SCDrop, along with corresponding biochips and immunostaining kits for cancer detection and treatment.

What is the over-allotment option in ADVB's IPO?

The underwriter has a 45-day option to purchase up to 246,000 additional shares at the public offering price to cover over-allotments.